We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Natural Killer Activity of Lymphocytes Infiltrating Human Lung Cancers Following Preoperative Systemic Recombinant Interleukin 2

Timothy M. Anderson, MD; Yukihiro Ibayashi, MD; Yutaka Tokuda, MD; Steve Colquhoun, MD; Carmack Holmes, MD; Sidney H. Golub, PhD
Arch Surg. 1987;122(12):1446-1450. doi:10.1001/archsurg.1987.01400240094017.
Text Size: A A A
Published online


• Tumor-infiltrating lymphocytes (TILs) show depressed natural killer (NK) activity compared with peripheral blood lymphocytes (PBLs). To determine if TIL NK function can be reactivated in vivo, 11 patients with tumors metastatic to the lung were treated with systemic recombinant interleukin 2 (rlL-2). Spontaneous TIL NK activity and NK activity after three days' incubation with 100 U/mL of rlL-2 were increased in patients receiving 15000 U/kg of rlL-2 preoperatively compared with those receiving between 1000 and 10000 U/kg. Histologically, higher doses of rlL-2 increased the number of intratumoral lymphocytes, the level of peritumoral lymphocytic transferrin, and the expression of HLA-DR. Spontaneous PBL NK activity in patients receiving between 10000 and 15000 U/kg of rlL-2 was also increased and was further increased by in vitro culture with rlL-2. Thus, PBL NK activity and TIL NK function in vivo can be augmented with 15000 U/kg of systemic rlL-2. Both TIL- and PBL-inducible cytotoxicities were further enhanced by in vitro culture with rlL-2.

(Arch Surg 1987;122:1446-1450)


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.